Alpha-synuclein targeting therapies represent one of the most active areas of drug development for Parkinson's disease and related synucleinopathies. This page provides comprehensive information about alpha-synuclein biology, therapeutic approaches, clinical development pipeline, and future directions.
Alpha-synuclein (α-syn) is a natively unfolded neuronal protein that plays a central role in the pathogenesis of Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). The aggregation of α-syn into toxic oligomers and fibrils is a hallmark of these neurodegenerative disorders, making it a high-priority therapeutic target.
Therapeutic strategies targeting α-syn include: reducing protein production, enhancing clearance, preventing aggregation, and neutralizing toxic species. Multiple approaches are now in clinical development across various phases.
¶ Structure and Function
- Protein family: Synuclein family (α-syn, β-syn, γ-syn)
- Primary expression: Presynaptic terminals in the brain
- Normal function: Synaptic vesicle trafficking, neurotransmitter release regulation
- Pathological forms: Oligomers, fibrils, Lewy bodies, glial cytoplasmic inclusions
Nucleation-dependent polymerization: The conversion from native α-syn to pathological aggregates follows a nucleation-dependent mechanism:
- Native monomer: Unstructured, soluble protein
- Oligomeric intermediates: Toxic soluble oligomers ("misfolded")
- Fibrils: insoluble protein fibrils
- Lewy bodies: Large intracellular inclusions
Key aggregation drivers:
- Gene multiplication (SNCA duplication/triplication)
- Point mutations (A30P, E46K, H50Q, G51D, A53T)
- Post-translational modifications (phosphorylation, ubiquitination)
- Metal ion binding (Fe³⁺, Cu²⁺)
- Cellular stress conditions
Synaptic dysfunction: α-syn aggregation disrupts:
- Synaptic vesicle recycling
- Dopamine release
- Mitochondrial function at synapses
- Axonal transport
Neuronal toxicity mechanisms:
- Membrane pore formation by oligomers
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
- Lysosomal dysfunction
- Neuroinflammation propagation
Small molecule aggregation inhibitors:
- Anle138b: Oligomer modulator that binds to toxic oligomers, reducing aggregation
- Curcumin and derivatives: Natural compounds that can inhibit aggregation
- NPT100-18A: Engineered protein that prevents α-syn aggregation
- SynuClean-D: Small molecule that inhibits α-syn fibrillation
Mechanism: These compounds bind to specific regions of α-syn (particularly the NACore and C-terminal domains) to prevent the conformational transition from monomer to oligomer/fibril.
Active vaccination:
- PD01A (Affiris): Peptide-based vaccine targeting phosphorylated α-syn (pSer129)
- ACI-35 (AC Immune): Liposome-based vaccine targeting phosphorylated α-syn
Passive immunotherapy:
- Prasinezumab (Roche): Monoclonal antibody targeting aggregated α-syn
- Cinpanemab (Biogen): Monoclonal antibody targeting α-syn oligomers
- BIIB054 (BMS): Monoclonal antibody targeting α-syn fibrils
- ABBV-0805 (AbbVie/Lundbeck): Monoclonal antibody targeting pathological α-syn
Mechanism: Antibodies are designed to:
- Target and neutralize circulating α-syn oligomers
- Enhance microglial clearance of extracellular aggregates
- Prevent cell-to-cell transmission of α-syn
RNA interference (RNAi):
- SNCA-targeting shRNA: Reduces α-syn expression via viral vector delivery
- MicroRNA-based approaches: AAV-delivered miR-7 or miR-153 targeting SNCA
Antisense oligonucleotides (ASOs):
- ASO targeting SNCA mRNA: Reduces production of α-syn protein
- IONIS-HTTRx derivatives: Similar chemistry applied to SNCA
Gene replacement:
- GDNF delivery: Does not directly target α-syn but provides neuroprotection
- NRTN (Neurturin): Gene therapy approach for neuroprotection
Autophagy enhancement:
- Rapamycin/mTOR inhibitors: Enhance macroautophagy
- Trehalose: Autophagy enhancer with anti-aggregation properties
- Natural compounds: Spermidine, urolithin A
Lysosomal enhancement:
- GCase modulators: Glucocerebrosidase (GBA) modifiers
- Cathepsin D enhancers: Enhance lysosomal protein degradation
- Small molecule activators: Pharmacological chaperones
Ubiquitin-proteasome enhancement:
- Proteasome activators: Enhance degradation of misfolded proteins
- Heat shock protein inducers: Hsp70, Hsp90 modulators
Neuroprotective compounds:
- Inosine: Elevates urate levels (antioxidant)
- CoQ10 and analogs: Mitochondrial function support
- Neurotrophic factors: BDNF, GDNF delivery approaches
Anti-inflammatory approaches:
- NLRP3 inhibitors: Target neuroinflammation
- Minocycline: Antibiotic with anti-inflammatory properties
- Sargramostim (GM-CSF): Immunomodulation approach
| Drug |
Company |
Mechanism |
Status |
| Prasinezumab |
Roche |
Anti-α-syn antibody |
Phase 2b completed |
| Cinpanemab |
Biogen |
Anti-α-syn antibody |
Phase 2 completed |
| Anle138b |
MODAG |
Aggregation inhibitor |
Phase 1/2 completed |
| Drug |
Company |
Mechanism |
Status |
| ABBV-0805 |
AbbVie/Lundbeck |
Anti-α-syn antibody |
Phase 1 completed |
| NPT100-18A |
Neuraly |
Aggregation inhibitor |
Phase 1 completed |
| UCBO913 |
UCB |
α-syn RNA modulator |
Phase 1 ongoing |
| Drug |
Company |
Mechanism |
Status |
| PD01A |
Affiris |
Active vaccine |
Phase 1 completed |
| ACI-35 |
AC Immune |
Active vaccine |
Phase 1b completed |
| BIIB054 |
BMS |
Anti-α-syn antibody |
Phase 1 completed |
- Total α-syn in CSF: Decreased in PD/DLB (seeded aggregation assay)
- pSer129 α-syn: Phosphorylated form, increased in CSF/血液
- Oligomeric α-syn: Toxic oligomer levels in CSF
- Neurofilament light chain (NfL): Neurodegeneration marker
- DaTscan (FP-CIT): Dopamine transporter imaging
- PK PET ligands: Pre-synaptic terminal imaging
- α-syn PET ligands: Emerging imaging tools
- MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale
- MoCA: Montreal Cognitive Assessment
- DATATOP endpoints: Motor symptoms, disability measures
- Non-motor symptom scales: Sleep, autonomic function
- SNCA multiplication: Higher α-syn burden, aggressive disease
- GBA carriers: Accelerated progression, target for GCase modulators
- LRRK2 carriers: Typical α-syn pathology, different therapeutic response
- Pre-motor PD: Prodromal α-syn targeting
- Early PD: Optimal window for disease modification
- Advanced PD: Symptomatic benefit, less disease modification
- pSer129 positive: Confirmed α-syn pathology
- Oligomer-positive: Higher likelihood of treatment response
- NfL elevation: Active neurodegeneration
¶ Challenges and Future Directions
- Blood-brain barrier penetration: Many therapeutics cannot reach CNS targets
- Aggregation vs. physiological function: Balancing reduction of toxic aggregation
- Cell-to-cell transmission: Preventing spread of pathology
- Biomarker development: Need better patient stratification
- Trial design: Long trials needed for disease modification endpoints
- Multi-target therapies: Combined mechanisms
- Personalized medicine: Genetic stratification
- Early intervention: Pre-symptomatic treatment
- Regenerative approaches: Cell replacement, gene therapy
- Combination therapies: Multiple mechanisms simultaneously
- α-syn PET imaging: Better visualization of pathology burden
- Seeding assays: ultrasensitive detection of pathological α-syn
- Gene editing: CRISPR-based approaches to modify SNCA
- Stem cell therapies: Cell replacement with engineered cells
The study of Alpha Synuclein Targeting Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.